Your browser doesn't support javascript.
loading
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
Popmihajlov, Zoran; Sutherland, Donna J; Horan, Gerald S; Ghosh, Atalanta; Lynch, David A; Noble, Paul W; Richeldi, Luca; Reiss, Theodore F; Greenberg, Steven.
Afiliación
  • Popmihajlov Z; Bristol Myers Squibb, Princeton, New Jersey, USA zoran.popmihajlov@bms.com.
  • Sutherland DJ; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Horan GS; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Ghosh A; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Lynch DA; Department of Radiology, National Jewish Health, Denver, Colorado, USA.
  • Noble PW; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Richeldi L; Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli IRCSS, Rome, Italy.
  • Reiss TF; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Greenberg S; Bristol Myers Squibb, Princeton, New Jersey, USA.
BMJ Open Respir Res ; 9(1)2022 Jan.
Article en En | MEDLINE | ID: mdl-35058236

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Pulmonares Intersticiales / Inhibidores de Proteínas Quinasas / Fibrosis Pulmonar Idiopática Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Idioma: En Revista: BMJ Open Respir Res Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Pulmonares Intersticiales / Inhibidores de Proteínas Quinasas / Fibrosis Pulmonar Idiopática Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Idioma: En Revista: BMJ Open Respir Res Año: 2022 Tipo del documento: Article